André N. Vis

Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial

Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis et al. · European Urology · 2018 · 554 citations

Urology, Radiation Medicine, Radiation Therapy +7

PROSTATE CANCER DETECTION AT LOW PROSTATE SPECIFIC ANTIGEN

Fritz H. Schröder, Ingrid van der Cruijsen‐Koeter, Harry J. de Koning et al. · The Journal of Urology · 2000 · 323 citations

Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome

Bas W.G. van Rhijn, André N. Vis, Theodorus van der Kwast et al. · Journal of Clinical Oncology · 2003 · 319 citations

<b> <i>FGFR3</i> </b> and <b> <i>P53</i> </b> Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma

Bas W.G. van Rhijn, Theodorus van der Kwast, André N. Vis et al. · Cancer Research · 2004 · 219 citations · Full text

Tumor Biology, P53 Alterations, Urology +15

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, André N. Vis et al. · European Urology · 2010 · 190 citations

Urology, Cancer Risk, Urologic Cancer Epidemiology +9